Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
Alpha-1 antitrypsin deficiency (AATD) is an inherited condition that causes the liver to make an abnormal protein. Instead of moving into the bloodstream as it should, this protein gets trapped inside liver cells. Over time, this build-up can cause inflammation and mild scarring, known as fibrosis. Fazirsiran is a new investigational medicine designed to reduce how much of this abnormal protein the liver makes. Researchers hope this will give the liver a chance to heal and stop scarring from getting worse. This Phase 3 trial compares fazirsiran to a dummy injection (placebo) over roughly two years. Participants will receive regular injections, attend clinic check-ups, and have two liver biopsies so doctors can look closely at their liver tissue. The goal is to see if the medicine is safe, well tolerated, and effective at protecting the liver.
At a glance
What is this study about?
The liver normally produces a protective protein called alpha-1 antitrypsin (AAT) and releases it into the blood to protect the lungs and other tissues. In people with a specific inherited form of alpha-1 antitrypsin deficiency, the liver produces an altered, sticky form of this protein. Because the protein cannot leave the liver easily, it builds up inside liver cells and causes irritation and mild scarring, called fibrosis. Without treatment, this damage can slowly increase over many years.
At present, there are very few approved treatments that directly address liver disease caused by this condition. Fazirsiran is an experimental medicine given by an injection under the skin. It works by turning down the genetic instructions that tell the liver to make the faulty protein. By clearing this backlog of protein, doctors hope to reduce liver irritation and potentially stop or reverse mild scarring.
This study is a Phase 3 clinical trial, which means researchers are testing the medicine in a wider group of people to confirm its benefits and look out for side effects. Half of the participants will receive fazirsiran, while the other half will receive a placebo, which looks identical but contains no active drug. This comparison helps doctors know for certain whether any health improvements are truly caused by the trial drug.
Finding an effective treatment early in the disease is vital. If fazirsiran succeeds, it could offer a new way to protect liver health for adults with this genetic condition before serious, long-term liver damage can develop.
Key takeaways
- Tests whether a new injection (fazirsiran) can safely reduce liver scarring in alpha-1 antitrypsin deficiency.
- Aimed at adults aged 18 to 75 with the confirmed PiZZ genetic type and mild liver scarring.
- Involves regular clinic appointments and study injections over roughly two years.
- Requires two liver biopsies to check how your liver tissue responds to treatment.
- Completely voluntary, with no changes to your standard NHS care if you choose not to join.
Who may be eligible?
This study is open to adults aged between 18 and 75 who have confirmed alpha-1 antitrypsin deficiency with a specific genetic type known as 'PiZZ'. Participants must already have mild liver scarring (known as stage F1 fibrosis), which is confirmed using a small sample of liver tissue called a biopsy.
To join, volunteers must be able to attend study visits, understand the trial steps, and complete electronic health questionnaires. If you take regular medicines for conditions like high blood pressure or cholesterol, your dosage must have been stable for at least eight weeks before starting the study.
You will not be able to take part if you have other genetic variations of the condition (such as PiMZ or PiSZ), if your liver disease has already advanced to severe scarring (cirrhosis), or if you have ever had liver cancer. The study doctor will check whether your overall lung and liver health meets the study guidelines.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you between 18 and 75 years of age?
- Do you have a confirmed PiZZ diagnosis of alpha-1 antitrypsin deficiency?
- Do you have mild liver scarring (stage F1 fibrosis)?
- Are you free from liver cancer?
- Are you comfortable having two liver biopsies during the two-year study?
- Can you attend regular hospital clinic visits and complete electronic health surveys?
What does participation involve?
Taking part in this study lasts for approximately two years. During this time, you will receive regular injections under the skin of either fazirsiran or a placebo. You will have scheduled visits at the hospital clinic for routine health checks, including physical exams, blood and urine tests, and heart tracings (ECGs). You will also complete short questionnaires on an electronic device to describe how you are feeling. To measure changes in your liver, you will need to have two liver biopsies during the trial: one near the start to confirm your eligibility, and one later in the study to check on your liver scarring.
Potential risks and benefits
Locations (41)
- St Joseph's Hospital and Medical CenterVerified postcodePhoenix, United States· Recruiting
- Mayo Clinic - PPDSVerified postcodePhoenix, United States· Recruiting
- University of Arizona Thomas D. Boyer Liver InstituteVerified postcodeTucson, United States· Recruiting
- University of California San DiegoVerified postcodeLa Jolla, United States· Recruiting
- UCLA Pulmonary and Critical CareVerified postcodeLos Angeles, United States· Recruiting
- University of California Benioff Children's HospitalVerified postcodeSan Francisco, United States· Recruiting
- Peak Gastroenterology AssociatesVerified postcodeColorado Springs, United States· Recruiting
- Schiff Center for Liver Diseases/University of MiamiVerified postcodeMiami, United States· Recruiting
- Indiana University School of Medicine-IndianapolisVerified postcodeIndianapolis, United States· Recruiting
- University Of Iowa Hospitals And ClinicsVerified postcodeIowa City, United States· Recruiting
- Boston Medical CenterVerified postcodeBoston, United States· Recruiting
- University of Michigan Hospital - 1500 E Medical Center DrVerified postcodeAnn Arbor, United States· Recruiting
Common questions
What is a placebo and why is it used?
A placebo is an inactive dummy treatment that looks just like the real medicine. It helps researchers fairly judge whether changes in health are due to the trial drug itself or other factors.
Will I know if I am receiving fazirsiran or the placebo?
No. Neither you nor your study doctor will know which treatment you are receiving during the study. This is called a double-blind trial and ensures the results are completely unbiased.
What is a liver biopsy and does it hurt?
A liver biopsy is a quick procedure where a doctor uses a thin needle to take a tiny sample of liver tissue. The area is numbed with local anaesthetic to minimise pain, though you may feel dull aching afterwards.
Does taking part cost anything?
No. The trial medicine, tests, and doctor visits are provided free of charge, and travel expenses are usually reimbursed by the study.
Can I stop taking part if I change my mind?
Yes. You have the right to withdraw from the study at any time, for any reason, and your regular doctor will continue to care for you as normal.
How to find out more
Takeda Contact
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.